FDA gave Illumina the greenlight to bring the first next-generation sequencing COVID-19 diagnostic test to the U.S. market, which is expected to become a key weapon in the battle against the virus. The test not only expands the United States' testing capabilities, but genetic sequencing information is expected to help scientists monitor if and how the virus mutates, which will be crucial as they continue to learn and fight the virus.
One molecular diagnostic company is cutting through the noise and reaching investors’ ears with a rapid COVID-19 test. Cue Health said Wednesday it has raised a sizeable $100 million in a series C financing to help support the development and commercialization of its tests, which includes a molecular diagnostic for COVID-19. Speaking of which, Cue Health finished out the week on a high note with FDA authorizing the rapid, portable, point-of-care molecular test designed to detect the RNA of SARS-CoV-2. The test uses a nasal swab sample taken from the lower part of the nose and produces results in 25 minutes, Cue said.
Bio Conscious Technologies says its AI-powered Diabits app is capable of predicting blood glucose levels an hour into the future, an improvement on industry-leading continuous glucose monitoring systems that offer 20-minute predictions. The company based the statement on an in-house study that involved the Padova simulator provided by the Epsilon Group, 30 virtual patients, and measured the predictive accuracy of the Diabits algorithm.